Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Amortization of Deferred Charges: 2020-2024

Historic Amortization of Deferred Charges for Seres Therapeutics (MCRB) over the last 4 years, with Sep 2024 value amounting to $463,000.

  • Seres Therapeutics' Amortization of Deferred Charges rose 17.81% to $463,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $1.8 million, marking a year-over-year increase of 106.58%. This contributed to the annual value of $1.4 million for FY2024, which is 24.06% up from last year.
  • According to the latest figures from Q3 2024, Seres Therapeutics' Amortization of Deferred Charges is $463,000, which was down 4.54% from $485,000 recorded in Q2 2024.
  • In the past 5 years, Seres Therapeutics' Amortization of Deferred Charges registered a high of $2.2 million during Q4 2021, and its lowest value of $118,000 during Q1 2021.
  • Its 3-year average for Amortization of Deferred Charges is $296,091, with a median of $225,000 in 2022.
  • Per our database at Business Quant, Seres Therapeutics' Amortization of Deferred Charges surged by 872.07% in 2021 and then crashed by 92.96% in 2022.
  • Seres Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $222,000 in 2020, then spiked by 872.07% to $2.2 million in 2021, then tumbled by 92.96% to $152,000 in 2022, then soared by 169.08% to $409,000 in 2023, then increased by 17.81% to $463,000 in 2024.
  • Its last three reported values are $463,000 in Q3 2024, $485,000 for Q2 2024, and $465,000 during Q1 2024.